nattokinase has been researched along with Hypertension* in 2 studies
1 trial(s) available for nattokinase and Hypertension
Article | Year |
---|---|
Effects of nattokinase on blood pressure: a randomized, controlled trial.
The objective of this study was to examine the effects of nattokinase supplementation on blood pressure in subjects with pre-hypertension or stage 1 hypertension. In a randomized, double-blind, placebo-controlled trial, 86 participants ranging from 20 to 80 years of age with an initial untreated systolic blood pressure (SBP) of 130 to 159 mmHg received nattokinase (2,000 FU/capsule) or a placebo capsule for 8 weeks. Seventy-three subjects completed the protocol. Compared with the control group, the net changes in SBP and diastolic blood pressure (DBP) were -5.55 mmHg (95% confidence interval [CI], -10.5 to -0.57 mmHg; p<0.05) and -2.84 mmHg (CI, -5.33 to -0.33 mmHg; p<0.05), respectively, after the 8-week intervention. The corresponding net change in renin activity was -1.17 ng/mL/h for the nattokinase group compared with the control group (p<0.05). In conclusion, nattokinase supplementation resulted in a reduction in SBP and DBP. These findings suggest that increased intake of nattokinase may play an important role in preventing and treating hypertension. Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Dietary Supplements; Female; Humans; Hypertension; Male; Middle Aged; Peptidyl-Dipeptidase A; Placebos; Renin; Soy Foods; Subtilisins; Treatment Outcome | 2008 |
1 other study(ies) available for nattokinase and Hypertension
Article | Year |
---|---|
Antihypertensive effects of continuous oral administration of nattokinase and its fragments in spontaneously hypertensive rats.
To determine whether the antihypertensive effect of nattokinase is associated with the protease activity of this enzyme, we compared nattokinase with the fragments derived from nattokinase, which possessed no protease activity, in terms of the effect on hypertension in spontaneously hypertensive rats (SHR). In the continuous oral administration test, the groups were given a basic diet alone (control), the basic diet containing nattokinase (0.2, 2.6 mg/g diet) or the basic diet containing the fragments derived from nattokinase (0.2, 0.6 mg/g diet). The group fed the basic diet containing high-dosage nattokinase (2.6 mg/g diet) showed significant reductions in systolic blood pressure (SBP), diastolic blood pressure (DBP) and plasma fibrinogen level, compared with control group and no influence on activities of renin and angiotensin-converting enzyme (ACE, EC 3.4.15.1), and plasma angiotensin II level in the renin-angiotensin system. The treatment of the basic diet containing high-dosage fragments (0.6 mg/g diet) significantly decreased SBP, DBP and plasma angiotensin II level in plasma but the treatment did not influence on plasma fibrinogen level. These results suggest that nattokinase and its fragments are different from each other in the mechanism to reduce hypertension. Nattokinase, retained its protease activity after absorbance across the intestines, may decrease blood pressure through cleavage of fibrinogen in plasma. The fragments, which absorbed as nattokinase-degradation products, prevents the elevation of plasma angiotensin II level to suppress hypertension. Topics: Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Fibrinogen; Glycine max; Hypertension; Intestinal Absorption; Male; Peptide Hydrolases; Phytotherapy; Plant Extracts; Rats; Rats, Inbred SHR; Soy Foods; Subtilisins | 2011 |